… One likely explanation is that many of the rare diseases for which drug development has
been pursued so far have a clear disease biology, such as well-defined genetic causes. …

… Better models and better understanding of disease mechanisms, drug development … target
multiple targets, and elaboration of disease biomarkers could produce the breakthrough that …

… drug development is tailoring the drug to the specific disease. This is dependent on a
thorough knowledge of the disease … Currently, drugs are developed either in normal rodents or …

… labeling of the drug [3•]. Modeling and simulation evaluation are therefore becoming more
commonly used during drug development. A concept used in drug development that has been …

… this complex have become appealing targets for drug development. In particular, ICE/caspase
1 has been the focus for small-molecule drug development. Pralnacasan (Aventis/Vertex) …

… In autoimmune diseases, they may act by inhibiting … (on the development of proteasome
inhibitors as drugs, and in … approach to drug development can be the development of small …

… One should, however, keep in mind (as discussed above) that NOD mice are born with a
hypofunctional TRPV1 and we cannot exclude a developmental compensatory mechanism that …

… by the US Food and Drug Administration (FDA) beginning in … biomarkers for use as drug
development tools 10 . The 21st … for the development of biomarkers as drug development tools …

… Rewards are given for successful drug development as a pull mechanism to promote
innovation [57]. Rewards can be designed in a variety of ways: to be specifically focused on one …

… therapeutically useful in curing and treating disease. This process involves the identification
… process of drug development earlier to clinical trials. New drug development process must …